FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.
Adam C. Fisher, PhD
Advertisement
Director of Science Staff, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA
Articles by Adam C. Fisher, PhD
Advertisement
Latest Updated Articles
The Manufacturing Edge on Path to MarketPublished: September 9th 2022 | Updated: September 22nd 2022
Advertisement
Advertisement
Trending on PharmExec
1
Real-World Data Brings New Insights to Natural History of Disease Studies
2
FDA Approves Hernexeos Under National Priority Voucher Program
3
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
4
Alkermes Reveals CEO Succession Plan Following Richard Pops’ Retirement Announcement
5